Comparison of plasma pharmacokinetics and bioequivalence of ceftiofur sodium in cattle after a single intramuscular or subcutaneous injection. J. vet. Pharmacol. Therap. 23,[273][274][275][276][277][278][279][280] Ceftiofur sodium, a broad-spectrum cephalosporin, is active against gram-positive and gram-negative pathogens of veterinary importance. This study was designed to compare the bioequivalence of the sodium salt in cattle after a single intramuscular (i.m.) or subcutaneous dose (s.c.) of 2.2 mg ceftiofur equivalents/kg body weight. The criteria used to evaluate bioequivalence were (1) the area under the curve from time of injection to the limit of quantitation (LOQ) of the assay (AUC 0-LOQ ), and (2) time concentrations remained above 0.2 mg/mL (t \ 0.2 ).
INTRODUCTION
Ceftiofur sodium, a broad-spectrum cephalosporin, is active against gram-positive and gram-negative pathogens of veterinary importance, including i-lactamase-producing strains, both in vitro and in vivo (Yancey et al., 1987) . Like other cephalosporins, ceftiofur isbactericidalinvitro,resultingfrominhibitionofcellwallsynthesis. The drug is approved for treatment of respiratory diseases of cattle, associated with Pasteurella haemolytica (Mannheimia spp), P. multocida and Haemophilus somnus, at doses of 1.1 −2.2 mg ceftiofur equivalents (CE)/kg body weight, administered intramuscularly (i.m.) for 3 -5 days (FDA, 1988 (FDA, , 1991 . Although injection site blemishes rarely occur with i.m. administration, escalating concern in the beef cattle industry over potential blemishes associated with i.m. administration of any product make subcutaneous (s.c.) administration an attractive alternative.
Ceftiofur sodium, regardless of its route of administration, is rapidly metabolized to desfuroylceftiofur. The plasma half-life after intravenous dosing in cattle is 7 min (Banting et al., 1989) . Parent ceftiofur is undetectable after 1 h in both cattle and swine (Brown et al., 1991) . Desfuroylceftiofur is the primary metabolite and the active moiety for both routes of administration.
Efficacy of i-lactam antibiotics is more closely related to time plasma concentrations that remain above a threshold, typically a multiple of the minimum inhibitory concentration (MIC) for the target pathogens, than to maximum plasma or tissue concentrations (Eagle et al., 1953; Joiner et al., 1982; FrimodtMøller et al., 1986; Peterson et al., 1984; Frimodt-Møller et al., 1987; Kays et al., 1991) . For that reason, bioequivalence was defined as the time concentrations of ceftiofur and metabolites (measured as desfuroylceftiofur acetamide by high-performance liquid chromatography (HPLC)) in plasma remained above a threshold concentration (0.2 mg/mL) set several-fold above the MIC.
This study compared the concentration-time profiles of ceftiofur sodium after single i.m. or s.c. injections. The variables assessed for bioequivalence were (1) the area under the concentration-time curve to the limit of quantitation of the assay (AUC LOQ ), and (2) time above 0.20 mg/mL (t \ 0.2 ), with maximum concentration (C max ) and time of observed maximum concentration (t max ) being recorded, but not used in decision making.
METHODS

Experimental animals and design
Twelve crossbred beef cattle (six steers and six heifers) were enrolled in a three-period, two-treatment crossover trial (ABB/ BAA), with a minimum 2-week washout period between doses of 2.2 mg CE/kg as ceftiofur sodium (NAXCEL ® /EXCENEL™ Sterile Powder, Pharmacia & Upjohn Company, Kalamazoo, MI, USA). The dose level represents the upper end of the approved dosage range in the US. Treatment A, using the s.c. route of administration, and treatment B used the i.m. route of administration. The i.m. injection into the neck region or s.c. injection into the manually tented skin of the neck region was performed using a 16-gauge, 1 1/2 inch needle. Injection sites alternated between the animals' right and left sides during the three periods. Study protocols were approved by the appropriate institutional animal care and use committees.
Blood sampling and analysis
Blood samples of 14 mL each were collected by venipuncture before drug administration, and at 20 min, 40 min, 1, 1.5, 2, 3, 4, 8, 16, 24, 36, 48, 60 and 72 h after each injection of 2.2 mg CE/kg. Each blood sample was collected in a heparinized container and stored on ice until processed into plasma. Plasma samples were analyzed using a validated assay that measures ceftiofur and all desfuroylceftiofur-related metabolites with an intact i-lactam ring by HPLC (Jaglan et al., 1990; Hamlow, 1995) . Because standard solutions were derived from ceftiofur reference standards, assay results were reported as CE in mg/ml, and summarized as means 9the standard deviation (SD). The limit of quantitation (LOQ) for the assay is 0.15 mg CE/mL of plasma. Values B LOQ were treated as 0 in the summary statistics.
Pharmacokinetic analysis
The trapezoidal rule was used to determine the area under the concentration-time curve from time 0 (the time of injection) to the last observation above the LOQ (AUC 0-LOQ ), the AUC from 0 to infinity (AUC 0 -)using the terminal rate constant (i), and the terminal phase half-life (t 1/2-i ) determined from MODEL 200 (trapezoidal method) from PCNONLIN, Version 4.0 (Statistical Consultants, Inc., Lexington, KY), observed maximum plasma concentration (C max ) and time of observed maximum plasma concentration (t max ). The time plasma concentrations remained above 0.2 mg/mL (t \ 0.2 ) was determined by linear regression of the terminal portion of the ln (concentration) vs. time curve or use of a predictive pharmacokinetic equation of the following forms:
where u i , are macrorate constants describing the apparent absorption and the various apparent elimination rate constants; C i , are coefficients; and t is the time in hours after drug administration. From the macrorate constants, the corresponding half-lives were calculated.
Fitting of those equations was achieved using nonlinear least squares regression analysis, also using PCNONLIN, Version 4.0, with a weighting factor of concentration − 1 . Goodness of fit between the two models was determined by Akaike's information criteria, residual trend evaluation of the terminal concentration-time points, and precision of parameter estimates.
Statistical analysis
To compare i.m. vs. s.c. administration, the study was designed as a three-period, two-treatment crossover design. The addition of an extra period dramatically reduces the two major drawbacks of the 2 ×2 crossover design-its lack of power in detecting (first order) carryover and the requirement that no carryover be present for the treatment comparisons to be unbiased. The extended period design is 'balanced' with respect to carryover in that each treatment not only follows the other treatment, but also follows itself. The test for carryover for the extended period design uses within-animal variance while the 2 × 2 crossover design uses between-animal variance. In addition, the test of treatment differences is independent of carryover, so the test is unbiased, even in its presence. The additional 90% confidence interval was − 1.33-2.15 mg CE/mL, completely contained within the 920% interval. The discrepancy between the two confidence intervals was a result of two outliers for which there was no apparent cause.
The AUC 0-LOQ by the trapezoidal method was 108 9 35.0 mg·h/mL after i.m. dosing, compared with 105 9 29.8 mg·h/mL after s.c. dosing. For AUC 0-LOQ the 90% non-parametric confidence interval of the difference between the two routes of administration was −10.1-20.4 mg·h/mL, which was contained within the 920% range of the mean for i.m. administration ( 9 21.9 mg·h/mL). Therefore, the criterion for equivalence of the AUC 0-LOQ for the i.m. and s.c. routes of administration was satisfied.
The observed t max ranged from 0.67-2 h after i.m. administration, whereas the observed t max after s.c. administration ranged from 0.67-3 h. These values were not significantly different between the two routes of administration.
The terminal phase t 1/2 , determined by the terminal data points above the LOQ using the output from the trapezoidal summation method, after i.m. administration was 10.7 9 3.11 h (harmonic mean =10.0 h), compared with 9.84 91.97 (harmonic mean = 9.47 h) after s.c. administration.
The plasma concentration vs. time data for both routes of administration were best described by a triexponential model with two disappearance rate constants and a single apparent absorption rate constant. From those data, the terminal elimination half-life was 13.4 94.95 h after s.c. administration, compared with 12.7 9 3.15 h after i.m. administration. The model-derived AUC comparisons were similar to those determined by the trapezoidal method, indicating that the data were well-behaved with regard to pharmacokinetic analysis.
The t \ 0.2 was 49.29 8.55 h after i.m. administration, compared with 47.0 9 9.40 h after s.c. administration. For t \ 0.2 the 90% non-parametric confidence interval of the difference between the two routes of administration ( − 2.5 to 10.0 h) was contained within 920% of the least square mean t \ 0.2 after i.m. administration ( 910.0 h). Therefore, the criterion for equivalence of the t \ 0.2 for i.m. and s.c. administration was satisfied.
DISCUSSION
Conventional bioequivalence studies evaluate peak concentration (C max ) and time to maximum concentration (t max ), in addition to AUC 0-LOQ , as the decision criteria regarding bioequivalence (Gibaldi & Perrier, 1982; Chow & Liu, 1992) . However, the literature for i-lactam antibiotics repeatedly reports that efficacy is not related as closely to maximum plasma or tissue concentrations as to the time concentrations, which remain above a certain threshold. Typically, the threshold is a multiple of the minimum inhibitory concentration (MIC) for the target pathogens (Eagle et al., 1953; Joiner et al., 1982; Peterson et al., 1984; Frimodt-Møller et al., 1986 Kays et al., 1991) . We believe that the time during which the concentration of ceftiofur and metabolites in plasma that is above such a observations beyond the 2 × 2 crossover design produce a 25% reduction in the variance of treatment difference, as well as twice the number of degrees of freedom for error, compared with the 2 × 2 crossover design (Chow & Liu, 1992) . Effects were considered statistically significant at an a level of 0.05 for a given response variable. The power associated with testing our hypothesis using h= 0.05 was calculated using both point estimate and upper 75% confidence limit for predetermined equivalence criteria.
Equivalence analysis
Two criteria were used to assess therapeutic equivalence: (1) AUC from time of injection to the LOQ of the assay (AUC 0-LOQ ), and (2) time concentrations remained above 0.2 mg/mL (t \ 0.2 ). C max and t max were tabulated but not used in the assessment of bioequivalence. The criteria for accepting bioequivalence was if the 90% confidence interval of the difference between the test formulation (s.c. administration) and the reference formulation (i.m. administration) for the variables AUC 0-LOQ and t \ 0.2 resided within 920% of the least square mean of the respective variables for the reference route of administration (i.m.).
RESULTS
All of the animals remained healthy throughout the study and no adverse reactions were observed. Fig. 1 shows the logarithm of plasma concentrations vs. time (X ( 9SD) for ceftiofur sodium after i.m. and s.c. administration. Individual animal pharmacokinetic data are provided in Tables 1-4 . These data are summarized for i.m. and s.c. routes in Table 5 . The C max of 13.993.55 mg/mL was observed from 0.67 −2.0 h after i.m. administration, whereas a C max of 13.6 93.85 mg/mL was observed from 0.67 −3.0 h after s.c. administration. For C max the 90% non-parametric confidence interval of the difference between the two routes of administration ( − 4.50 to 2.98 mg CE/ mL) was not contained within the interval of 9 20% of the i.m. least square mean ( 92.79 mg CE/mL). However, the t-based Table 1 
